10-Q: Simulations Plus Q1 2026: Net Income Up 228%, Revenue Down 3%

Simulations Plus, Inc. reported a significant 228% increase in net income to $0.7 million for Q1 fiscal year 2026, despite a 3% decline in total revenues to $18.4 million, driven by strong services growth and reduced operating expenses.

Summary

• Total revenues decreased by 3% to $18.4 million for the three months ended November 30, 2025, compared to $18.9 million for the same period in the prior year.
• Software revenue declined by 17% ($1.8 million) to $8.9 million, primarily due to decreases in Clinical Operations and Development solutions.
• Services revenue increased by 16% ($1.3 million) to $9.5 million, driven by organic growth in Commercialization ($0.8 million) and Development ($0.5 million).
• Net income surged by 228% to $0.7 million for the three months ended November 30, 2025, up from $0.2 million in the prior year.
• Diluted earnings per share increased to $0.03 for the current quarter, compared to $0.01 in the prior year.
• Gross profit rose by 7% to $10.9 million, with the overall gross margin improving to 59% from 54% year-over-year.
• Income from operations increased significantly by 466% to $0.7 million.
• Research and development (R&D) expenses increased by 61% to $3.0 million, reflecting higher investment in product and platform development.
• General and administrative (G&A) expenses decreased by 25% to $4.0 million, primarily due to lower corporate support costs and reduced non-recurring spending.
• Net cash provided by operating activities was $4.2 million, a $5.5 million improvement compared to a net cash use of $1.3 million in the prior year.
• Cash and cash equivalents stood at $30.2 million as of November 30, 2025, with net working capital of $47.8 million.

Sentiment

Score: 7

Explanation: The company demonstrated strong profitability growth, significant improvement in operating income, and robust cash flow from operations. The reduction in G&A expenses and continued investment in R&D are positive signs for future efficiency and innovation. However, the overall revenue decline, particularly in the software segment, presents a mixed picture that warrants careful monitoring.

Positives

• Net income increased by 228% to $0.7 million for the three months ended November 30, 2025.
• Diluted earnings per share rose to $0.03, up from $0.01 in the prior year.
• Services revenue grew by 16% to $9.5 million, driven by organic growth in Commercialization ($0.8 million) and Development ($0.5 million).
• Gross profit increased by 7% to $10.9 million, and gross margin improved to 59% from 54%.
• Income from operations saw a substantial increase of 466% to $0.7 million.
• General and administrative expenses decreased by 25% to $4.0 million, reflecting lower corporate support, reduced M&A costs, and optimized real estate footprint.
• Net cash provided by operating activities improved by $5.5 million year-over-year, reaching $4.2 million.
• Strong liquidity position with $30.2 million in cash and cash equivalents and $5.5 million in short-term investments.
• Management expects existing capital resources to be sufficient to fund operating activities and cash commitments for the next 12 months and beyond.

Negatives

• Total revenues decreased by 3% to $18.4 million for the three months ended November 30, 2025.
• Software revenue declined by 17% to $8.9 million, primarily due to a $1.4 million decrease in Clinical Operations and a $0.4 million decrease in Development solutions.
• Research and development (R&D) spend increased by 51% to $3.9 million, and as a percentage of revenue, it increased to 16% from 10%, indicating higher investment without immediate corresponding revenue growth.
• Income tax expense increased by 359% to $0.3 million, with the income tax rate rising to 30.3% from 23.7% due to non-recurring favorable discrete items in the prior year.
• The Pro-ficiency developed technology was impaired in the third quarter of fiscal year 2025, leading to less amortization but indicating a prior asset value reduction.

Risks

• The biopharma sector faces challenges in drug development, which is time-consuming and expensive, with an average cost of approximately $2.2 billion and 10-15 years per drug.
• Macro-economic issues, including global drug pricing, are causing a temporary reduction in R&D spending by pharmaceutical and biotech companies.
• Operating results could be significantly affected by the ability to develop new products and find new distribution channels for new and existing products.
• The biosimulation, simulation-enabled performance, and medical communications industry is highly competitive and changes rapidly.
• Strategic acquisitions, investments, and partnerships could require a substantial portion of cash reserves or necessitate financing options, potentially impacting liquidity and results of operations.
• Financial statements rely on significant estimates and assumptions, including revenue recognition, capitalized software development costs, intangible assets and goodwill valuation, stock options, business acquisitions, and income taxes, which could differ from actual results.
• Concentration of credit risk exists in cash, cash equivalents, trade accounts receivable, and short-term investments, with balances exceeding FDIC-insured limits held at a large national bank and a non-FDIC-insured bank in France.
• Revenue concentration is present, with the three largest customers accounting for 11%, 4%, and 3% of total revenues for the three months ended November 30, 2025.
• Accounts receivable concentrations show the three largest customers each comprising between 6% and 7% of accounts receivable as of November 30, 2025.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those indicated.

Future Outlook

The company expects existing cash, cash equivalents, short-term investments, cash generated by ongoing operations, and working capital to be sufficient to fund operating activities and cash commitments for the next 12 months and beyond. It continues to seek opportunities for strategic acquisitions, investments, and partnerships. Future amortization expense is expected to vary due to increases in capitalized computer software development costs, and the increased R&D spend represents a continued investment in innovation for future growth.

Management Comments

• Developing new therapies is time-consuming and expensive, requiring an average of 10-15 years and an average cost of approximately $2.2 billion to develop a single drug.
• Our MIDD software and services allow clients to use modeling and simulation to accelerate drug development, reduce the costs of R&D, comply with regulatory guidance and best practices, and increase confidence in the safety and efficacy of their drugs and biologics.
• Our adaptive learning solutions support the success of clinical trials by accelerating recruitment of an appropriate patient population, increasing retention of participants, and by driving competency and compliance with trial protocols, while our medical communications solutions provide support in obtaining regulatory approval and commercialization of drugs.
• The increase in R&D spend was primarily attributable to higher personnel-related costs, consistent with increased efforts to support these development initiatives, representing our continued investment in innovation for future growth.
• The decrease in G&A primarily reflected lower corporate support costs and reduced non-recurring spending, with facilities costs decreasing as we continued to optimize our real estate footprint consistent with a remote-first operating model.
• We continue to seek opportunities for strategic acquisitions, investments, and partnerships.

Industry Context

The biopharma industry faces significant challenges, including the lengthy and costly process of drug development (averaging 10-15 years and $2.2 billion per drug) and macro-economic pressures like global drug pricing, which are temporarily reducing R&D spending. Simulations Plus positions itself as a strategic partner, offering software and consulting services that integrate scientific platforms, AI-augmented insights, and expert consulting to optimize efficiency, costs, and time-to-market. The company's solutions aim to address these industry pain points by accelerating drug development, ensuring regulatory compliance, and enhancing clinical trial success in a highly competitive and rapidly evolving market.

Comparison to Industry Standards

• The company's solutions aim to mitigate the industry standard of 10-15 years and an average cost of $2.2 billion to develop a single drug, by accelerating drug development and reducing R&D costs.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any legal proceedings and is not aware of any pending or threatened legal proceedings of any kind.

Stakeholder Impact

• Shareholders: Positive impact from increased net income and EPS, improved gross margin, and strong cash flow from operations. Potential for future growth through R&D investment and strategic acquisitions.
• Employees: Continued investment in R&D suggests ongoing opportunities in product development. Prior headcount reduction in Q3 FY2025 impacted compensation-related costs.
• Customers: Benefit from continued investment in product and platform development, enhancing software offerings and capabilities. Services revenue growth indicates strong client engagement.
• Creditors: Strong liquidity position and positive cash flow from operations reduce credit risk.
• Directors: Changes in board composition with one resignation and one withdrawal of resignation, impacting governance structure and continuity.

Next Steps

• Continue to seek opportunities for strategic acquisitions, investments, and partnerships.
• Monitor the impact of recently issued accounting standards (ASU 2023-06, ASU 2023-09, ASU 2025-06, ASU 2025-10, ASU 2025-11) on financial statements.
• Manage estimated future amortization expense for finite-lived intangible assets for the remainder of fiscal year 2026 and subsequent years.

Key Dates

Recommendation

While the significant increase in net income and operating cash flow is very positive, the overall revenue decline, particularly in the software segment, and the substantial increase in R&D spend without immediate revenue growth present a mixed picture. The company's strategic investments in R&D and pursuit of acquisitions could drive future growth, but the current quarter shows a contraction in a key segment. The improved gross margin and reduced G&A are good signs of efficiency. A 'hold' recommendation reflects the balance between strong profitability and cash generation against the revenue challenges and the long-term nature of R&D investments.

Keywords

Biopharma, Drug Discovery, Drug Development, Clinical Trials, Software, Consulting Services, Pharmacokinetics, Pharmacodynamics, AI-driven prediction, Biosimulation, SEC 10-Q, Financial Results, Simulations Plus